The Science

Regulating cell metabolism to develop disease-modifying therapeutics to treat chronic autoimmune and inflammatory disease.

The Science of Sitryx

Focus on immunometabolism

The field of immunometabolism is an exciting area of medicine at the forefront of immunology research that stems from a growing understanding of how metabolic changes within immune system cells can drive severe disease

Metabolic pathways play a central role in regulating immune cell function and activation, with dysregulation across these pathways impacting immune response and contributing to the progression of chronic autoimmune and inflammatory disease.

Sitryx is building a broad pipeline of first- and best-in-class therapies by identifying novel targeted approaches based on how changes in metabolism modulate immune cell function.

Intervening in cell metabolism

Metabolic changes within cells of the immune system can drive the pathology of a disease. By intervening in cell metabolism, inflammation and tissue damage can be reversed and resolved, leading to better patient outcomes.

Metabolic changes can contribute to pathology

  • Normal Tissue
  • Acute Inflammation
  • Chronic Inflammation
  • Tissue Damage and Fibrosis

← Metabolic intervention can reverse changes

Broad-based impact to resolve disease

Most modern anti-inflammatory and oncology drugs intervene at a particular point causing immunosuppression with limited results. Changing the state of different combinations of immune cells can have a much more wide-ranging impact to potentially resolve inflammation.

Blocking Cytokines

Blocking cytokines at one particular point results in targeted immunosuppression and resolution of disease in a limited subset of patients.

Targeted Metabolic Intervention

Targeted metabolic intervention can shift cells to a non-inflammatory pro-resolution state, offering the potential for a broader population of patients to achieve disease remission.

Different diseases targeted through specific cell types

Different cells of the immune system are implicated in different diseases and hence different groups of cells of the immune system can be targeted by intervening at particular points of metabolism.

By targeting a range of points of metabolic control, Sitryx can build a portfolio across a range of diseases.

Augment Inhibit
Inflammatory macrophage
Pan-Inflamm T-cell*
Th1 cell
Th17 cell
T Reg cell
B cell
Stromal Cells
Profile 1MS, psoriasis, atopic dermatitis, RA, fibrosis
Profile 2IBD, diabetic nephropathy, RA, psoriasis, HS
Profile 3SLE, atopic dermatitis, psoriasis, ankylosing spondylitis, myasthenia gravis
Profile 4IPF, asthma, COPD
Profile 5IBD, asthma, psoriasis, Sjogren's disease
MS = Multiple Sclerosis, A = Rheumatoid Arthritis, HS = Hidradenitis Suppurativa, IBD= Inflammatory Bowel Disease, SLE = Systemic Lupus Erythematosus, IPF = Idiopathic Pulmonary Fibrosis, COPD = Chronic Obstructive Pulmonary Disease
*Potentially includes the subsets of Th1 and Th17 cells